Cti Biopharma reported $29.79M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Applied Genetic Technologies AGTC:US $ 25.21M 0.6M
Baxter International BAX:US $ 3916M 26M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Cti Biopharma CTIC:US $ 29.79M 69.14M
Cytori Therapeutics CYTX:US $ 6.97M 2.05M
Eli Lilly And LLY:US $ 15620.6M 2234.6M
Geron GERN:US $ 46.88M 0.25M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Northwest Biotherapeutics NWBO:US 98.16M 31.85M
Novartis NOVN:VX SF 27646M 2161M
Novartis NVS:US $ 27646M 2161M
Seattle Genetics SGEN:US $ 608.52M 77.23M
Teva Pharmaceutical Industries TEVA:US $ 10996M 617M
YTE INCY:US $ 926.67M 40.51M